Cargando…

Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial

BACKGROUND: A cardioprotective role of morphine acting via opioid receptors has been demonstrated, and previous preclinical studies have reported that morphine could reduce reperfusion injury and myocardial infarct size in a way similar to that of ischemic periconditioning. This study aimed to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwag, Hye Bin, Kim, Eun Kyoung, Park, Taek Kyu, Lee, Joo Myung, Yang, Jeong Hoon, Song, Young Bin, Choi, Jin‐Ho, Choi, Seung‐Hyuk, Lee, Sang Hoon, Chang, Sung‐A, Park, Sung‐Ji, Lee, Sang‐Chol, Park, Seung Woo, Jang, Woo Jin, Lee, Mirae, Chun, Woo Jung, Oh, Ju Hyeon, Park, Yong Hwan, Choe, Yeon Hyeon, Gwon, Hyeon‐Cheol, Hahn, Joo‐Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533032/
https://www.ncbi.nlm.nih.gov/pubmed/28373244
http://dx.doi.org/10.1161/JAHA.116.005426
_version_ 1783253567489966080
author Gwag, Hye Bin
Kim, Eun Kyoung
Park, Taek Kyu
Lee, Joo Myung
Yang, Jeong Hoon
Song, Young Bin
Choi, Jin‐Ho
Choi, Seung‐Hyuk
Lee, Sang Hoon
Chang, Sung‐A
Park, Sung‐Ji
Lee, Sang‐Chol
Park, Seung Woo
Jang, Woo Jin
Lee, Mirae
Chun, Woo Jung
Oh, Ju Hyeon
Park, Yong Hwan
Choe, Yeon Hyeon
Gwon, Hyeon‐Cheol
Hahn, Joo‐Yong
author_facet Gwag, Hye Bin
Kim, Eun Kyoung
Park, Taek Kyu
Lee, Joo Myung
Yang, Jeong Hoon
Song, Young Bin
Choi, Jin‐Ho
Choi, Seung‐Hyuk
Lee, Sang Hoon
Chang, Sung‐A
Park, Sung‐Ji
Lee, Sang‐Chol
Park, Seung Woo
Jang, Woo Jin
Lee, Mirae
Chun, Woo Jung
Oh, Ju Hyeon
Park, Yong Hwan
Choe, Yeon Hyeon
Gwon, Hyeon‐Cheol
Hahn, Joo‐Yong
author_sort Gwag, Hye Bin
collection PubMed
description BACKGROUND: A cardioprotective role of morphine acting via opioid receptors has been demonstrated, and previous preclinical studies have reported that morphine could reduce reperfusion injury and myocardial infarct size in a way similar to that of ischemic periconditioning. This study aimed to evaluate the effect of intracoronary morphine on myocardial infarct size in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention. METHODS AND RESULTS: This study was designed as a 2‐center, prospective, randomized, open‐label, blinded end point trial. A total of 91 ST‐elevation myocardial infarction patients with thrombolysis in myocardial infarction flow grade of 0 to 1 undergoing primary percutaneous coronary intervention were randomly assigned to a morphine or control group at a 1:1 ratio. The morphine group received 3 mg of morphine sulfate diluted with 3 mL of normal saline, and the control group received 3 mL of normal saline into a coronary artery immediately after restoration of coronary flow. The primary end point was myocardial infarct size assessed by cardiac magnetic resonance imaging The cardiac magnetic resonance images were evaluated for 42 and 38 patients in the morphine and control groups, respectively. Myocardial infarct size was not different between the 2 groups (25.6±11.2% versus 24.6±10.5%, P=0.77), nor was the extent of microvascular obstruction or myocardial salvage index (6.0±6.3% versus 5.1±4.6%, P=0.91; 31.1±15.2% versus 30.3±10.9%, P=0.75, respectively). There was no difference in peak creatine kinase‐MB level, final thrombolysis in myocardial infarction flow, myocardial brush grade, or complete resolution of ST‐segment. CONCLUSIONS: Intracoronary morphine administration could not reduce myocardial infarct size in ST‐elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01738100.
format Online
Article
Text
id pubmed-5533032
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55330322017-08-14 Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial Gwag, Hye Bin Kim, Eun Kyoung Park, Taek Kyu Lee, Joo Myung Yang, Jeong Hoon Song, Young Bin Choi, Jin‐Ho Choi, Seung‐Hyuk Lee, Sang Hoon Chang, Sung‐A Park, Sung‐Ji Lee, Sang‐Chol Park, Seung Woo Jang, Woo Jin Lee, Mirae Chun, Woo Jung Oh, Ju Hyeon Park, Yong Hwan Choe, Yeon Hyeon Gwon, Hyeon‐Cheol Hahn, Joo‐Yong J Am Heart Assoc Original Research BACKGROUND: A cardioprotective role of morphine acting via opioid receptors has been demonstrated, and previous preclinical studies have reported that morphine could reduce reperfusion injury and myocardial infarct size in a way similar to that of ischemic periconditioning. This study aimed to evaluate the effect of intracoronary morphine on myocardial infarct size in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention. METHODS AND RESULTS: This study was designed as a 2‐center, prospective, randomized, open‐label, blinded end point trial. A total of 91 ST‐elevation myocardial infarction patients with thrombolysis in myocardial infarction flow grade of 0 to 1 undergoing primary percutaneous coronary intervention were randomly assigned to a morphine or control group at a 1:1 ratio. The morphine group received 3 mg of morphine sulfate diluted with 3 mL of normal saline, and the control group received 3 mL of normal saline into a coronary artery immediately after restoration of coronary flow. The primary end point was myocardial infarct size assessed by cardiac magnetic resonance imaging The cardiac magnetic resonance images were evaluated for 42 and 38 patients in the morphine and control groups, respectively. Myocardial infarct size was not different between the 2 groups (25.6±11.2% versus 24.6±10.5%, P=0.77), nor was the extent of microvascular obstruction or myocardial salvage index (6.0±6.3% versus 5.1±4.6%, P=0.91; 31.1±15.2% versus 30.3±10.9%, P=0.75, respectively). There was no difference in peak creatine kinase‐MB level, final thrombolysis in myocardial infarction flow, myocardial brush grade, or complete resolution of ST‐segment. CONCLUSIONS: Intracoronary morphine administration could not reduce myocardial infarct size in ST‐elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01738100. John Wiley and Sons Inc. 2017-04-03 /pmc/articles/PMC5533032/ /pubmed/28373244 http://dx.doi.org/10.1161/JAHA.116.005426 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Gwag, Hye Bin
Kim, Eun Kyoung
Park, Taek Kyu
Lee, Joo Myung
Yang, Jeong Hoon
Song, Young Bin
Choi, Jin‐Ho
Choi, Seung‐Hyuk
Lee, Sang Hoon
Chang, Sung‐A
Park, Sung‐Ji
Lee, Sang‐Chol
Park, Seung Woo
Jang, Woo Jin
Lee, Mirae
Chun, Woo Jung
Oh, Ju Hyeon
Park, Yong Hwan
Choe, Yeon Hyeon
Gwon, Hyeon‐Cheol
Hahn, Joo‐Yong
Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial
title Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial
title_full Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial
title_fullStr Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial
title_full_unstemmed Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial
title_short Cardioprotective Effects of Intracoronary Morphine in ST‐Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial
title_sort cardioprotective effects of intracoronary morphine in st‐segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a prospective, randomized trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533032/
https://www.ncbi.nlm.nih.gov/pubmed/28373244
http://dx.doi.org/10.1161/JAHA.116.005426
work_keys_str_mv AT gwaghyebin cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT kimeunkyoung cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT parktaekkyu cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT leejoomyung cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT yangjeonghoon cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT songyoungbin cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT choijinho cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT choiseunghyuk cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT leesanghoon cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT changsunga cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT parksungji cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT leesangchol cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT parkseungwoo cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT jangwoojin cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT leemirae cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT chunwoojung cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT ohjuhyeon cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT parkyonghwan cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT choeyeonhyeon cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT gwonhyeoncheol cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial
AT hahnjooyong cardioprotectiveeffectsofintracoronarymorphineinstsegmentelevationmyocardialinfarctionpatientsundergoingprimarypercutaneouscoronaryinterventionaprospectiverandomizedtrial